Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
Richard Coker;
(2002)
Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
The international journal of tuberculosis and lung disease, 6 (8).
pp. 649-650.
ISSN 1027-3719
https://material-uat.leaf.cosector.com/id/eprint/17607
| Item Type | Article |
|---|---|
| Keywords | Antitubercular Agents/*therapeutic use, *Communicable Disease Control/economics, Cost-Benefit Analysis, Costs and Cost Analysis, Human, Tuberculosis, Multidrug-Resistant/*drug therapy |
| ISI | 177114800002 |